IPSC.mesodermal_primed: Studies — page 11
How association tiers are defined — cell–trait and gene–trait
SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.
Cell–trait tiers
- Cell–trait links
- Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
- Required for Specific or Relevant
- The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
- Specific (Tier 1)
- Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
- Relevant (Tier 2)
- Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
- Interpretation and report values
- CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
- Meta traits and individual traits
- Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.
Gene–trait priorities (variant–tCRE–gene evidence)
- Variant–tCRE–gene links
- Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
- Required genetic support
- The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
- Required cellular support
- The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
- High priority
- Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
- Medium priority
- Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
- Same-record evidence and aggregation
- Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
- Limits of interpretation
- A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.
State · 1,329 full-atlas cells · all tissues.
Marker genes and cell annotation · Open this population in Cell Browser →
ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.
Rows 10,001–11,000 of 12,313; ranked by score descending. Equal values use name/identifier order.
| # | Trait / study | Individual trait ID | Mean IC score |
|---|---|---|---|
| 10001 | CX3CL1/PODXL2 ratio | GCST90314326 | 2.77e-03 |
| 10002 | CD22/FCRL1 ratio | GCST90313757 | 2.76e-03 |
| 10003 | FYB1/PPP1R12A ratio | GCST90314913 | 2.76e-03 |
| 10004 | Plasma pregnenetriol disulfate* levels in chronic kidney disease | GCST90265864 | 2.75e-03 |
| 10005 | Weight-to-muscle ratio | GCST90267359 | 2.74e-03 |
| 10006 | DOK2 levels | GCST90469029 | 2.74e-03 |
| 10007 | CCNE1 levels | GCST90468593 | 2.74e-03 |
| 10008 | DCXR levels | GCST90468964 | 2.73e-03 |
| 10009 | VEGFC levels | GCST90471036 | 2.73e-03 |
| 10010 | MSTN/RGMA ratio | GCST90315504 | 2.72e-03 |
| 10011 | White blood cell count | GCST004610 | 2.72e-03 |
| 10012 | Smoking status (weighted GWA) | GCST90267303 | 2.71e-03 |
| 10013 | GP2/SELE ratio | GCST90314962 | 2.71e-03 |
| 10014 | QC T2 FLAIR-to-T1 linear alignment discrepancy | GCST90006350 | 2.70e-03 |
| 10015 | Hard cheese liking | GCST90094778 | 2.70e-03 |
| 10016 | IDO1 levels | GCST90469506 | 2.70e-03 |
| 10017 | Disorders of the thyroid gland | FING00000463 | 2.67e-03 |
| 10018 | Varicose veins | circulatory system | UKBB00000893 | 2.66e-03 |
| 10019 | CSF1/IL10RB ratio | GCST90314284 | 2.66e-03 |
| 10020 | DIABLO/PDGFB ratio | GCST90314468 | 2.65e-03 |
| 10021 | CSF1 levels | GCST90468881 | 2.65e-03 |
| 10022 | BCR/DECR1 ratio | GCST90313489 | 2.65e-03 |
| 10023 | Asthma (only as main-diagnosis) (more control exclusions) | FING00000114 | 2.64e-03 |
| 10024 | ATG4A/NSFL1C ratio | GCST90313368 | 2.63e-03 |
| 10025 | Endometrial cancer | GCST006464 | 2.62e-03 |
| 10026 | Asthma, unspecified (mode) | FING00000120 | 2.61e-03 |
| 10027 | MMP3 levels | GCST90012027 | 2.59e-03 |
| 10028 | EVI5 levels | GCST90469158 | 2.58e-03 |
| 10029 | SHISA5 levels | GCST90470626 | 2.58e-03 |
| 10030 | HEG1 levels | GCST90469444 | 2.57e-03 |
| 10031 | FUT8/RSPO1 ratio | GCST90314891 | 2.57e-03 |
| 10032 | IDP SWI T2star right putamen | GCST90003868 | 2.57e-03 |
| 10033 | GP6/SELP ratio | GCST90314970 | 2.56e-03 |
| 10034 | OMD/SOST ratio | GCST90315585 | 2.56e-03 |
| 10035 | COL1A1/OMD ratio | GCST90314171 | 2.56e-03 |
| 10036 | Plasma X-25279 levels in chronic kidney disease | GCST90266835 | 2.55e-03 |
| 10037 | DEFA1 or DEFA1B levels | GCST90468979 | 2.54e-03 |
| 10038 | ThalamNuclei lh volume VLp | GCST90002734 | 2.54e-03 |
| 10039 | Glycine levels | GCST90497316 | 2.53e-03 |
| 10040 | MGLL/MITD1 ratio | GCST90315436 | 2.53e-03 |
| 10041 | Dihexosylceramide (d18:1/24:0) levels | GCST90025349 | 2.53e-03 |
| 10042 | CLPP levels | GCST90468785 | 2.52e-03 |
| 10043 | Autoimmune hyperthyroidism | FING00000134 | 2.51e-03 |
| 10044 | DAG1/PLA2G4A ratio | GCST90314380 | 2.51e-03 |
| 10045 | Operation year/age first occurred | Operations | UKBB00000570 | 2.51e-03 |
| 10046 | MED18/TACC3 ratio | GCST90315414 | 2.50e-03 |
| 10047 | MPI/TACC3 ratio | GCST90315491 | 2.50e-03 |
| 10048 | CCL4 levels | GCST90012052 | 2.49e-03 |
| 10049 | CRACR2A levels | GCST90468853 | 2.49e-03 |
| 10050 | MOG/PTPRN2 ratio | GCST90315475 | 2.48e-03 |
| 10051 | Prescriptions - thyroid hormone | hormone | UKBB00000705 | 2.48e-03 |
| 10052 | Prescriptions - levothyroxine | thyroid hormone | UKBB00000687 | 2.48e-03 |
| 10053 | CD300LG/DSG2 ratio | GCST90313802 | 2.47e-03 |
| 10054 | Sicca syndrome [Sjögren] | FING00001304 | 2.46e-03 |
| 10055 | F-fruit liking (derived food-liking factor) | GCST90094767 | 2.45e-03 |
| 10056 | FUCA1 levels | GCST90469275 | 2.44e-03 |
| 10057 | Varicose veins of lower extremities | Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified | UKBB00000894 | 2.42e-03 |
| 10058 | STX8/USP8 ratio | GCST90315896 | 2.41e-03 |
| 10059 | Depression (broad) | GCST005902 | 2.40e-03 |
| 10060 | PCDH17/ROBO1 ratio | GCST90315604 | 2.39e-03 |
| 10061 | Cholesteryl esters to total lipids ratio in large LDL | GCST90092859 | 2.39e-03 |
| 10062 | SCLY levels | GCST90470546 | 2.39e-03 |
| 10063 | Rheumatoid arthritis | GCST000679 | 2.39e-03 |
| 10064 | PSCA levels | GCST90470352 | 2.39e-03 |
| 10065 | NOTCH1/TIE1 ratio | GCST90315546 | 2.38e-03 |
| 10066 | Phosphatidylcholine-O_36:4_[M+H]1+/Phosphatidylcholine-P_36:3_[M+H]1+ levels | GCST90060318 | 2.38e-03 |
| 10067 | DOK2/PPP1R12A ratio | GCST90314536 | 2.37e-03 |
| 10068 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 70) | GCST90320889 | 2.37e-03 |
| 10069 | Platelet distribution width | Blood count | UKBB00000648 | 2.36e-03 |
| 10070 | BIN2/TMSB10 ratio | GCST90313515 | 2.36e-03 |
| 10071 | Total Sphingomyelin levels | GCST90025842 | 2.36e-03 |
| 10072 | Spermatocele (PheCode 603.2) | GCST90476158 | 2.35e-03 |
| 10073 | aparc-a2009s lh area G-cingul-Post-ventral | GCST90003306 | 2.35e-03 |
| 10074 | Illnesses of father - None of the above (group 2) | Family history | UKBB00000346 | 2.35e-03 |
| 10075 | FURIN/IGSF3 ratio | GCST90314885 | 2.34e-03 |
| 10076 | ARHGAP30 levels | GCST90468354 | 2.34e-03 |
| 10077 | TGFBI/VASN ratio | GCST90315915 | 2.34e-03 |
| 10078 | Lung cancer in never smokers | GCST90277434 | 2.34e-03 |
| 10079 | Urine methylsuccinoylcarnitine levels in chronic kidney disease | GCST90265509 | 2.33e-03 |
| 10080 | EGLN1/FOXO1 ratio | GCST90314616 | 2.32e-03 |
| 10081 | MTHFSD levels | GCST90469956 | 2.31e-03 |
| 10082 | Cholesteryl esters to total lipids in large LDL percentage (UKB data field 23616) | GCST90269713 | 2.31e-03 |
| 10083 | Broad bean liking | GCST90094711 | 2.30e-03 |
| 10084 | Osteopenia or other disorder of bone and cartilage (PheCode 743.9) | GCST90476261 | 2.30e-03 |
| 10085 | RGMB levels | GCST90242647 | 2.30e-03 |
| 10086 | AHSP/CA2 ratio | GCST90313215 | 2.29e-03 |
| 10087 | Cholelithiasis | GCST90468118 | 2.29e-03 |
| 10088 | CELA3A/PLA2G1B ratio | GCST90314014 | 2.28e-03 |
| 10089 | NAP1L4 levels | GCST90469998 | 2.27e-03 |
| 10090 | Microscopic colitis | GCST90204144 | 2.27e-03 |
| 10091 | FGF21 levels | GCST90274788 | 2.27e-03 |
| 10092 | Neoplasm of uncertain behavior of skin (PheCode 173) | GCST90475585 | 2.26e-03 |
| 10093 | HDLBP levels | GCST90087533 | 2.26e-03 |
| 10094 | Heterophoria | FING00000620 | 2.25e-03 |
| 10095 | GOLGA3 levels | GCST90469375 | 2.25e-03 |
| 10096 | Blood cell traits latent factor 14 (red cell) | GCST90559256 | 2.24e-03 |
| 10097 | ThalamNuclei lh volume CM | GCST90002718 | 2.24e-03 |
| 10098 | T1 CAT volume L VIIIa | GCST90384127 | 2.23e-03 |
| 10099 | Viral and other specified intestinal infections | FING00001432 | 2.23e-03 |
| 10100 | Acute sinusitis | FING00000031 | 2.23e-03 |
| 10101 | Asthma | GCST006862 | 2.22e-03 |
| 10102 | Tyrosine levels | GCST90243425 | 2.22e-03 |
| 10103 | Father's age at death | Family history | UKBB00000241 | 2.22e-03 |
| 10104 | CD58 levels | GCST90468638 | 2.21e-03 |
| 10105 | NFATC3 levels | GCST90470034 | 2.21e-03 |
| 10106 | rfMRI connectivity (ICA100 edge 995) | GCST90005848 | 2.21e-03 |
| 10107 | MIF/PARK7 ratio | GCST90315447 | 2.21e-03 |
| 10108 | DNAJC6 levels | GCST90469017 | 2.20e-03 |
| 10109 | TNFRSF1A levels | GCST90012015 | 2.20e-03 |
| 10110 | GP1BA/SIAE ratio | GCST90314959 | 2.20e-03 |
| 10111 | GSTA3 levels | GCST90469412 | 2.19e-03 |
| 10112 | N-acetylcarnosine levels | GCST90199926 | 2.19e-03 |
| 10113 | THTPA levels | GCST90470860 | 2.18e-03 |
| 10114 | LY6D levels | GCST90469821 | 2.18e-03 |
| 10115 | CDH15 levels | GCST90468668 | 2.18e-03 |
| 10116 | CHRDL2 levels | GCST90468751 | 2.17e-03 |
| 10117 | Sjögren's syndrome | GCST90018700 | 2.17e-03 |
| 10118 | Disorders of bilirubin excretion (PheCode 277.4) | GCST90475756 | 2.17e-03 |
| 10119 | IL15RA levels | GCST90469555 | 2.16e-03 |
| 10120 | Diffuse idiopathic skeletal hyperostosis flow score | GCST90134532 | 2.16e-03 |
| 10121 | Urine N1,N12-diacetylspermine levels in chronic kidney disease | GCST90265683 | 2.15e-03 |
| 10122 | Special factor anxiety/tension in mitochondrial haplogroup U | GCST90264127 | 2.15e-03 |
| 10123 | Benign neoplasm: Colon | FING00000171 | 2.15e-03 |
| 10124 | Linoleic acid levels | GCST90502311 | 2.15e-03 |
| 10125 | Oral glucose tolerance test-2h | GCST90566423 | 2.14e-03 |
| 10126 | ANGPT1/EGF ratio | GCST90313264 | 2.14e-03 |
| 10127 | Cholelithiasis | GCST90018599 | 2.14e-03 |
| 10128 | Total concentration of lipoprotein particles | GCST90500103 | 2.14e-03 |
| 10129 | Left-hemisphere control network to right-hemisphere dorsal attention network white-matter structural connectivity | GCST90302747 | 2.14e-03 |
| 10130 | Other infective otitis externa | FING00001060 | 2.14e-03 |
| 10131 | CEBPB/NADK ratio | GCST90314006 | 2.12e-03 |
| 10132 | SEMA4C levels | GCST90470572 | 2.11e-03 |
| 10133 | Cataracts | GCST90018594 | 2.11e-03 |
| 10134 | rfMRI amplitudes (ICA100 node 40) | GCST90004628 | 2.11e-03 |
| 10135 | aparc-a2009s rh thickness G+S-cingul-Ant | GCST90003682 | 2.11e-03 |
| 10136 | Retention of urine (PheCode 599.2) | GCST90476150 | 2.10e-03 |
| 10137 | Biological Sibling: Cancer, Skin | GCST90476369 | 2.10e-03 |
| 10138 | APP levels | GCST90468344 | 2.09e-03 |
| 10139 | Cervicobrachial syndrome | FING00000266 | 2.09e-03 |
| 10140 | FCRL5/ICAM3 ratio | GCST90314802 | 2.08e-03 |
| 10141 | NID1 levels | GCST90470047 | 2.08e-03 |
| 10142 | Other and unspecified rosacea | FING00000951 | 2.07e-03 |
| 10143 | Ulcerative colitis | GCST90468152 | 2.06e-03 |
| 10144 | F-dessert liking (derived food-liking factor) | GCST90094754 | 2.06e-03 |
| 10145 | Physical activity (Total log acceleration) | GCST90061408 | 2.06e-03 |
| 10146 | BIN1 levels | GCST90090757 | 2.05e-03 |
| 10147 | Hippocampal subfield left CA3 volume (body) | GCST90267940 | 2.04e-03 |
| 10148 | Allergy/adverse effect of penicillin | injuries & poisonings | UKBB00000028 | 2.04e-03 |
| 10149 | Asthma (more control exclusions) | FING00000113 | 2.04e-03 |
| 10150 | PF4 levels | GCST90470211 | 2.03e-03 |
| 10151 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T237 | ECGU000237 | 2.03e-03 |
| 10152 | PLA2G4A/SNX9 ratio | GCST90315670 | 2.03e-03 |
| 10153 | MMP10 levels | GCST90469915 | 2.03e-03 |
| 10154 | CDC27 levels | GCST90468664 | 2.03e-03 |
| 10155 | KLK15 levels | GCST90469701 | 2.02e-03 |
| 10156 | KIFBP/TACC3 ratio | GCST90315249 | 2.02e-03 |
| 10157 | Pregnanediol-3-glucuronide levels | GCST90199917 | 2.01e-03 |
| 10158 | CD40/TNFRSF14 ratio | GCST90313830 | 2.00e-03 |
| 10159 | NECTIN2/NPDC1 ratio | GCST90315528 | 2.00e-03 |
| 10160 | PPP1R9B levels | GCST90470305 | 1.99e-03 |
| 10161 | Alkenylphosphatidylcholine (P-16:0/16:0) levels | GCST90025563 | 1.99e-03 |
| 10162 | Abdominal subcutaneous adipose tissue volume | GCST90016672 | 1.98e-03 |
| 10163 | Cauliflower liking | GCST90094727 | 1.97e-03 |
| 10164 | SPRY2/YTHDF3 ratio | GCST90315881 | 1.97e-03 |
| 10165 | Pulse wave Arterial Stiffness index | Arterial stiffness | UKBB00000724 | 1.97e-03 |
| 10166 | DNAJB1/METAP2 ratio | GCST90314509 | 1.97e-03 |
| 10167 | CD244/FCRL6 ratio | GCST90313765 | 1.96e-03 |
| 10168 | MTSS1 levels | GCST90469960 | 1.96e-03 |
| 10169 | IL6 expression at 6 weeks in whole blood upon Bbmix moi30 stimulation in Lyme borreliosis | GCST90275789 | 1.95e-03 |
| 10170 | Retinal venular width | GCST90270400 | 1.95e-03 |
| 10171 | Mean platelet volume | GCST004599 | 1.94e-03 |
| 10172 | MET/PTPRF ratio | GCST90315435 | 1.94e-03 |
| 10173 | NFATC1 levels | GCST90470033 | 1.94e-03 |
| 10174 | APP/BIN2 ratio | GCST90313316 | 1.93e-03 |
| 10175 | Myasthenia gravis | GCST90093061 | 1.93e-03 |
| 10176 | MGLL/STK4 ratio | GCST90315443 | 1.93e-03 |
| 10177 | DLK1 levels | GCST90469003 | 1.92e-03 |
| 10178 | Cerebrospinal fluid methylmalonate (MMA) levels | GCST90318243 | 1.92e-03 |
| 10179 | Red blood cell count | GCST004601 | 1.91e-03 |
| 10180 | MCFD2 levels | GCST90469873 | 1.91e-03 |
| 10181 | Chronic lower respiratory diseases | FING00000290 | 1.91e-03 |
| 10182 | HCLS1/LAT ratio | GCST90315041 | 1.91e-03 |
| 10183 | Gamma glutamyl transpeptidase | GCST90018734 | 1.91e-03 |
| 10184 | CELA3A/KIRREL2 ratio | GCST90314013 | 1.90e-03 |
| 10185 | Urate levels | GCST001791 | 1.90e-03 |
| 10186 | CD79B levels | GCST90468648 | 1.90e-03 |
| 10187 | CLEC4M levels | GCST90468775 | 1.90e-03 |
| 10188 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475452 | 1.90e-03 |
| 10189 | Docosahexaenoic acid levels | GCST90502258 | 1.90e-03 |
| 10190 | Autorefraction - 6mm strong meridian angle (left) | Eyesight | UKBB00000077 | 1.89e-03 |
| 10191 | HDAC8 levels | GCST90469438 | 1.89e-03 |
| 10192 | TNFRSF1B levels | GCST90012026 | 1.89e-03 |
| 10193 | ENG/TNFRSF10C ratio | GCST90314650 | 1.89e-03 |
| 10194 | SORT1/ST6GAL1 ratio | GCST90315869 | 1.88e-03 |
| 10195 | Abdominal subcutaneous adipose tissue | GCST90267347 | 1.88e-03 |
| 10196 | Visceral adipose tissue | GCST90267357 | 1.88e-03 |
| 10197 | Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity | GCST90302834 | 1.87e-03 |
| 10198 | COX5B/FXN ratio | GCST90314199 | 1.87e-03 |
| 10199 | SYAP1 levels | GCST90470792 | 1.87e-03 |
| 10200 | CD40LG/TNFSF14 ratio | GCST90313827 | 1.86e-03 |
| 10201 | FCRL2/KLB ratio | GCST90314798 | 1.86e-03 |
| 10202 | Degeneration of macula and posterior pole of retina (PheCode 362.2) | GCST90475849 | 1.85e-03 |
| 10203 | MESD/WWP2 ratio | GCST90315426 | 1.85e-03 |
| 10204 | BCR/ITGB1BP2 ratio | GCST90313494 | 1.85e-03 |
| 10205 | NUDT5/TXNRD1 ratio | GCST90315582 | 1.84e-03 |
| 10206 | CLMP/PIK3IP1 ratio | GCST90314134 | 1.84e-03 |
| 10207 | FXN/METAP1D ratio | GCST90314897 | 1.83e-03 |
| 10208 | CRACR2A/DNMBP ratio | GCST90314226 | 1.83e-03 |
| 10209 | Hernia abdominopelvic cavity | GCST90086087 | 1.82e-03 |
| 10210 | CD69/CEP43 ratio | GCST90313867 | 1.82e-03 |
| 10211 | CERT/PRTFDC1 ratio | GCST90314029 | 1.81e-03 |
| 10212 | KIR2DL3 levels | GCST90469685 | 1.81e-03 |
| 10213 | CRISP3 levels | GCST90468866 | 1.80e-03 |
| 10214 | FCER2/FCRL1 ratio | GCST90314789 | 1.80e-03 |
| 10215 | ALDH1A1/RBKS ratio | GCST90313247 | 1.79e-03 |
| 10216 | Alkylphosphatidylcholine (O-32:1) levels | GCST90024923 | 1.79e-03 |
| 10217 | PPP1R12A/VEGFC ratio | GCST90315715 | 1.79e-03 |
| 10218 | wg rh intensity-contrast transversetemporal | GCST90003860 | 1.79e-03 |
| 10219 | HPCAL1/LAT ratio | GCST90315072 | 1.78e-03 |
| 10220 | ERBIN/SNAP29 ratio | GCST90314697 | 1.78e-03 |
| 10221 | SPARC/TACC3 ratio | GCST90315872 | 1.77e-03 |
| 10222 | TACC3/TBC1D23 ratio | GCST90315900 | 1.77e-03 |
| 10223 | Other specified disorders of external ear | FING00001104 | 1.75e-03 |
| 10224 | NPC2 levels | GCST90470068 | 1.75e-03 |
| 10225 | CCN1 levels | GCST90468587 | 1.75e-03 |
| 10226 | Intestinal infectious diseases | FING00000689 | 1.75e-03 |
| 10227 | RAB11FIP3 levels | GCST90470404 | 1.74e-03 |
| 10228 | CRLF1 levels | GCST90468868 | 1.74e-03 |
| 10229 | CWC15 levels | GCST90468920 | 1.74e-03 |
| 10230 | Unspecified acute lower respiratory infection | FING00001398 | 1.74e-03 |
| 10231 | DARS1 levels | GCST90468947 | 1.73e-03 |
| 10232 | CLEC4G/NELL2 ratio | GCST90314122 | 1.73e-03 |
| 10233 | Other disorders of veins | FING00001040 | 1.72e-03 |
| 10234 | CRIM1 levels | GCST90468863 | 1.72e-03 |
| 10235 | Phospholipids in very large HDL | GCST90500451 | 1.72e-03 |
| 10236 | NECTIN4 levels | GCST90470021 | 1.72e-03 |
| 10237 | Hair colour (natural, before greying): Light brown (UKB data field 1747_3) | GCST90041838 | 1.72e-03 |
| 10238 | CXCL5/SPARC ratio | GCST90314355 | 1.72e-03 |
| 10239 | NBL1/TGFBR2 ratio | GCST90315515 | 1.71e-03 |
| 10240 | C1QA levels | GCST90468485 | 1.71e-03 |
| 10241 | Melanomas of skin, dx or hx (PheCode 172.1) | GCST90475577 | 1.71e-03 |
| 10242 | IDP dMRI TBSS MO Medial lemniscus L | GCST90003961 | 1.71e-03 |
| 10243 | Disorders of lacrimal system | FING00000441 | 1.71e-03 |
| 10244 | PPP1R2/TACC3 ratio | GCST90315719 | 1.70e-03 |
| 10245 | NPDC1/TAFA5 ratio | GCST90315550 | 1.70e-03 |
| 10246 | Sphingomyelin (d18:1/14:0) levels/Sphingomyelin (d16:1/16:0) levels | GCST90025115 | 1.69e-03 |
| 10247 | NTN1 levels | GCST90242047 | 1.69e-03 |
| 10248 | White blood cell count | GCST90002375 | 1.69e-03 |
| 10249 | Pulse wave peak to peak time | Arterial stiffness | UKBB00000725 | 1.68e-03 |
| 10250 | CA5A levels | GCST90468514 | 1.68e-03 |
| 10251 | WFDC5 levels | GCST90089598 | 1.68e-03 |
| 10252 | CD244/EDAR ratio | GCST90313764 | 1.68e-03 |
| 10253 | Other non-epithelial cancer of skin | neoplasms | UKBB00000615 | 1.68e-03 |
| 10254 | GNPDA2 levels | GCST90469374 | 1.66e-03 |
| 10255 | CX3CL1/EPHB6 ratio | GCST90314324 | 1.66e-03 |
| 10256 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T485 | ECGA000485 | 1.65e-03 |
| 10257 | Varicose veins of lower extremity | circulatory system | UKBB00000895 | 1.65e-03 |
| 10258 | Use of antiglaucoma preparations and miotics | FING00001409 | 1.64e-03 |
| 10259 | Status post-ami | FING00001333 | 1.64e-03 |
| 10260 | Ectopic pregnancy | GCST90272883 | 1.64e-03 |
| 10261 | ICD10 O00: Ectopic pregnancy | GCST90454227 | 1.64e-03 |
| 10262 | FCGR2A/FCGR2B ratio | GCST90314793 | 1.63e-03 |
| 10263 | SSC4D/TNFSF10 ratio | GCST90315887 | 1.63e-03 |
| 10264 | FYB1/PDGFB ratio | GCST90314912 | 1.63e-03 |
| 10265 | SH3BP1 levels | GCST90470619 | 1.62e-03 |
| 10266 | Blood cell traits latent factor 12 (red cell) | GCST90559254 | 1.62e-03 |
| 10267 | DFFA/FOXO1 ratio | GCST90314456 | 1.62e-03 |
| 10268 | Lysophosphatidylcholine (24:0) [sn2] levels | GCST90025426 | 1.62e-03 |
| 10269 | TMSB10/ZBTB16 ratio | GCST90315926 | 1.61e-03 |
| 10270 | Type 2 diabetes | GCST90086071 | 1.60e-03 |
| 10271 | Non-cancer illness code, self-reported - glaucoma | Medical conditions | UKBB00000511 | 1.60e-03 |
| 10272 | IGBP1 levels | GCST90469521 | 1.60e-03 |
| 10273 | KDR levels | GCST90469672 | 1.60e-03 |
| 10274 | Loud music exposure frequency | Hearing | UKBB00000410 | 1.59e-03 |
| 10275 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T484 | ECGA000484 | 1.59e-03 |
| 10276 | ICD10 O26.6: Liver disorders in pregnancy, childbirth and puerperium | GCST90454237 | 1.59e-03 |
| 10277 | MANSC1/PODXL ratio | GCST90315372 | 1.58e-03 |
| 10278 | TIMP4 levels | GCST90470872 | 1.58e-03 |
| 10279 | PSAP levels | GCST90470351 | 1.58e-03 |
| 10280 | SNRPB2 levels | GCST90470697 | 1.58e-03 |
| 10281 | SULT2A1 levels | GCST90470782 | 1.57e-03 |
| 10282 | TAX1BP1 levels | GCST90470808 | 1.57e-03 |
| 10283 | GZMA levels | GCST90241323 | 1.57e-03 |
| 10284 | HCLS1/TMSB10 ratio | GCST90315043 | 1.57e-03 |
| 10285 | BLVRB/HAGH ratio | GCST90313524 | 1.55e-03 |
| 10286 | CD40/CRELD2 ratio | GCST90313811 | 1.55e-03 |
| 10287 | Right-hemisphere visual network to right-hemisphere dorsal attention network white-matter structural connectivity | GCST90302776 | 1.55e-03 |
| 10288 | Acute bronchitis | FING00000021 | 1.55e-03 |
| 10289 | CA12 levels | GCST90468507 | 1.55e-03 |
| 10290 | Flavonifractor sp002159265 abundance in stool | GCST90032400 | 1.54e-03 |
| 10291 | Cancer of urinary organs (incl. kidney and bladder) (PheCode 189) | GCST90475593 | 1.54e-03 |
| 10292 | SNX15 levels | GCST90470699 | 1.54e-03 |
| 10293 | CDSN/LY6D ratio | GCST90313997 | 1.54e-03 |
| 10294 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T483 | ECGA000483 | 1.53e-03 |
| 10295 | PGF levels | GCST90011999 | 1.52e-03 |
| 10296 | Acute appendicitis | FING00000017 | 1.51e-03 |
| 10297 | Breast cancer | GCST90018579 | 1.51e-03 |
| 10298 | Alkylphosphatidylcholine (O-16:0/16:0) levels | GCST90024913 | 1.51e-03 |
| 10299 | OTUD6B levels | GCST90470136 | 1.50e-03 |
| 10300 | FKBP5/MITD1 ratio | GCST90314844 | 1.50e-03 |
| 10301 | CEACAM8/MMP9 ratio | GCST90314002 | 1.50e-03 |
| 10302 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24) | GCST90320587 | 1.50e-03 |
| 10303 | GPR15L levels | GCST90469396 | 1.50e-03 |
| 10304 | AXIN1/SRPK2 ratio | GCST90313417 | 1.49e-03 |
| 10305 | Nontoxic uninodular goiter (PheCode 241.1) | GCST90475640 | 1.49e-03 |
| 10306 | ANG/RARRES2 ratio | GCST90313271 | 1.49e-03 |
| 10307 | FOXJ3 levels | GCST90469264 | 1.48e-03 |
| 10308 | Lysophosphatidylcholine (22:0) [sn2] levels | GCST90024176 | 1.48e-03 |
| 10309 | NAGK levels | GCST90469995 | 1.48e-03 |
| 10310 | BMP10 levels | GCST90468452 | 1.47e-03 |
| 10311 | EBI3_IL27/VCAM1 ratio | GCST90314572 | 1.47e-03 |
| 10312 | CDKN2D/FOXO1 ratio | GCST90313985 | 1.46e-03 |
| 10313 | Wheeze or whistling in the chest in last year (UKB data field 2316) | GCST90043614 | 1.46e-03 |
| 10314 | GUCA2A/LGALS4 ratio | GCST90314998 | 1.46e-03 |
| 10315 | KLK11/KLK8 ratio | GCST90315254 | 1.45e-03 |
| 10316 | FCAR/LY96 ratio | GCST90314788 | 1.45e-03 |
| 10317 | Physical activity | GCST90093322 | 1.45e-03 |
| 10318 | Sleep apnea with BMI < 30 | GCST90624797 | 1.45e-03 |
| 10319 | BAG6/BMP6 ratio | GCST90313450 | 1.45e-03 |
| 10320 | LAT/VASH1 ratio | GCST90315289 | 1.44e-03 |
| 10321 | ESAM/VSIR ratio | GCST90314721 | 1.44e-03 |
| 10322 | ENO2/MGLL ratio | GCST90314663 | 1.44e-03 |
| 10323 | Brussel sprout liking | GCST90094714 | 1.44e-03 |
| 10324 | ABL1/PDLIM7 ratio | GCST90313150 | 1.43e-03 |
| 10325 | BOLA2 or BOLA2B levels | GCST90468460 | 1.42e-03 |
| 10326 | BACH1/CD2AP ratio | GCST90313435 | 1.42e-03 |
| 10327 | DTI TBSS MO Medial lemniscus R | GCST90384628 | 1.42e-03 |
| 10328 | CA4/SELE ratio | GCST90313587 | 1.41e-03 |
| 10329 | METAP2/RILP ratio | GCST90315433 | 1.41e-03 |
| 10330 | ENG/NCAM2 ratio | GCST90314647 | 1.41e-03 |
| 10331 | DECR1/FXN ratio | GCST90314446 | 1.41e-03 |
| 10332 | T1 CAT volume R RightThalamus | GCST90384097 | 1.41e-03 |
| 10333 | JAM2/RGMB ratio | GCST90315237 | 1.41e-03 |
| 10334 | creatinine (minimum, inv-norm transformed) | GCST90475232 | 1.41e-03 |
| 10335 | FADD/NFATC1 ratio | GCST90314771 | 1.41e-03 |
| 10336 | FCER2/TCL1A ratio | GCST90314790 | 1.40e-03 |
| 10337 | FUT8/SPARC ratio | GCST90314893 | 1.40e-03 |
| 10338 | IL10RB levels | GCST90469545 | 1.39e-03 |
| 10339 | MICB or MICA levels | GCST90469905 | 1.39e-03 |
| 10340 | Attendance/disability/mobility allowance - Disability living allowance | Other sociodemographic factors | UKBB00000058 | 1.38e-03 |
| 10341 | PPME1 levels | GCST90470298 | 1.38e-03 |
| 10342 | PLIN1/SNCG ratio | GCST90315677 | 1.38e-03 |
| 10343 | Right-hemisphere visual network to right-hemisphere default mode network white-matter structural connectivity | GCST90302780 | 1.38e-03 |
| 10344 | LYPD8 levels | GCST90469829 | 1.37e-03 |
| 10345 | Calcium levels | GCST90025990 | 1.37e-03 |
| 10346 | CXCL9 levels | GCST90468935 | 1.37e-03 |
| 10347 | Right-hemisphere dorsal attention network to pallidum white-matter structural connectivity | GCST90302809 | 1.37e-03 |
| 10348 | CDC42BPB levels | GCST90468666 | 1.37e-03 |
| 10349 | RARRES2/ST6GAL1 ratio | GCST90315759 | 1.36e-03 |
| 10350 | Serum phosphate levels | GCST90025948 | 1.36e-03 |
| 10351 | Autoimmune diseases excluding thyroid diseases | FING00000132 | 1.36e-03 |
| 10352 | Biological Father: Cancer, Skin | GCST90475240 | 1.35e-03 |
| 10353 | Blood cell traits latent factor 3 (white cell) | GCST90559245 | 1.35e-03 |
| 10354 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T491 | ECGA000491 | 1.35e-03 |
| 10355 | LAMA4/PDGFB ratio | GCST90315273 | 1.35e-03 |
| 10356 | CCL13 levels | GCST90468565 | 1.35e-03 |
| 10357 | CHI3L1/PRSS8 ratio | GCST90314044 | 1.34e-03 |
| 10358 | CD22/FCER2 ratio | GCST90313756 | 1.34e-03 |
| 10359 | F7/PROC ratio | GCST90314744 | 1.34e-03 |
| 10360 | Preterm labour and delivery | FING00001209 | 1.34e-03 |
| 10361 | Platelet distribution width | GCST90002401 | 1.34e-03 |
| 10362 | AHSG levels | GCST90468263 | 1.34e-03 |
| 10363 | Myasthenia gravis | GCST90432156 | 1.33e-03 |
| 10364 | Osteoporosis | FING00000914 | 1.33e-03 |
| 10365 | ASGR2 levels | GCST90468376 | 1.33e-03 |
| 10366 | HTRA2/SIAE ratio | GCST90315097 | 1.32e-03 |
| 10367 | MIF/SUSD2 ratio | GCST90315452 | 1.32e-03 |
| 10368 | TNFRSF13B/TNFRSF9 ratio | GCST90315932 | 1.32e-03 |
| 10369 | BIN2/FYB1 ratio | GCST90313505 | 1.31e-03 |
| 10370 | CDNF levels | GCST90468686 | 1.31e-03 |
| 10371 | NHLRC3 levels | GCST90470046 | 1.31e-03 |
| 10372 | IGFBP3 levels | GCST90102624 | 1.31e-03 |
| 10373 | TAFA5 levels | GCST90470800 | 1.30e-03 |
| 10374 | DKK1/ZBTB16 ratio | GCST90314486 | 1.30e-03 |
| 10375 | CCN2/SPINT2 ratio | GCST90313716 | 1.29e-03 |
| 10376 | DNAJA2/HCLS1 ratio | GCST90314502 | 1.29e-03 |
| 10377 | MANF/PRDX5 ratio | GCST90315365 | 1.29e-03 |
| 10378 | SOD3 levels | GCST90470706 | 1.29e-03 |
| 10379 | IDP dMRI TBSS ISOVF Corticospinal tract R | GCST90004483 | 1.29e-03 |
| 10380 | Hypothyroidism (PheCode 244) | GCST90475647 | 1.28e-03 |
| 10381 | DCTN1/FXN ratio | GCST90314430 | 1.28e-03 |
| 10382 | Alanine aminotransferase levels | GCST90278617 | 1.28e-03 |
| 10383 | Citrulline levels | GCST90243458 | 1.28e-03 |
| 10384 | GP6/LGALS8 ratio | GCST90314964 | 1.27e-03 |
| 10385 | X-21736 levels | GCST90200584 | 1.27e-03 |
| 10386 | PSAP levels | GCST90426586 | 1.27e-03 |
| 10387 | CLIP2/DAB2 ratio | GCST90314124 | 1.27e-03 |
| 10388 | Lignoceroylcarnitine (C24) levels | GCST90200137 | 1.26e-03 |
| 10389 | Facial pigmentation measurement (polar light) | GCST90002284 | 1.26e-03 |
| 10390 | DNAJB2 levels | GCST90469013 | 1.26e-03 |
| 10391 | KRT18 levels | GCST90469716 | 1.26e-03 |
| 10392 | LY6D/NECTIN4 ratio | GCST90315344 | 1.26e-03 |
| 10393 | GKN2 levels | GCST90089413 | 1.26e-03 |
| 10394 | Blood urea nitrogen levels | GCST90018728 | 1.26e-03 |
| 10395 | PRTFDC1 levels | GCST90470346 | 1.26e-03 |
| 10396 | SMAD2 levels | GCST90470676 | 1.25e-03 |
| 10397 | APP/PPP1R12A ratio | GCST90313330 | 1.25e-03 |
| 10398 | TNFRSF4 levels | GCST90470913 | 1.25e-03 |
| 10399 | HippSubfield rh volume presubiculum-body | GCST90002697 | 1.25e-03 |
| 10400 | CXCL16/NOTCH1 ratio | GCST90314339 | 1.25e-03 |
| 10401 | CRIP2/SNCG ratio | GCST90314262 | 1.24e-03 |
| 10402 | aparc-a2009s lh area S-precentral-sup-part | GCST90003365 | 1.24e-03 |
| 10403 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502077 | 1.24e-03 |
| 10404 | Cardiometabolic multimorbidity | GCST90274723 | 1.24e-03 |
| 10405 | NOTCH3/PTPRS ratio | GCST90315547 | 1.24e-03 |
| 10406 | Omega-3 fatty acid levels | GCST90502064 | 1.24e-03 |
| 10407 | SPINT1 levels | GCST90241717 | 1.24e-03 |
| 10408 | Actinic keratosis (PheCode 702.1) | GCST90476204 | 1.23e-03 |
| 10409 | Gouty arthropathy (PheCode 274.11) | GCST90475738 | 1.22e-03 |
| 10410 | ECE1 levels | GCST90469061 | 1.22e-03 |
| 10411 | MANF/SNX9 ratio | GCST90315368 | 1.22e-03 |
| 10412 | PLA2G2A levels | GCST90470247 | 1.21e-03 |
| 10413 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 88) | GCST90320907 | 1.20e-03 |
| 10414 | Disorders of muscles | FING00000444 | 1.20e-03 |
| 10415 | CASP8/PPP3R1 ratio | GCST90313654 | 1.20e-03 |
| 10416 | SCT levels | GCST90470557 | 1.20e-03 |
| 10417 | SEPTIN8 levels | GCST90470578 | 1.20e-03 |
| 10418 | NCR3 levels | GCST90088179 | 1.20e-03 |
| 10419 | NOMO1 levels | GCST90470060 | 1.20e-03 |
| 10420 | Seropositive rheumatoid arthritis, strict definition | FING00001297 | 1.19e-03 |
| 10421 | GIT1 levels | GCST90469351 | 1.19e-03 |
| 10422 | Wheeze or whistling in the chest in last year | Breathing | UKBB00000912 | 1.19e-03 |
| 10423 | CDH5/NOTCH1 ratio | GCST90313957 | 1.19e-03 |
| 10424 | MPIG6B/SUSD1 ratio | GCST90315487 | 1.19e-03 |
| 10425 | IL6ST/LIFR ratio | GCST90315166 | 1.19e-03 |
| 10426 | FXYD5 levels | GCST90469283 | 1.19e-03 |
| 10427 | Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels | GCST90060395 | 1.19e-03 |
| 10428 | CDH17/SPINT1 ratio | GCST90313944 | 1.19e-03 |
| 10429 | TPMT levels | GCST90470945 | 1.18e-03 |
| 10430 | WNT9A levels | GCST90471079 | 1.17e-03 |
| 10431 | DTI autoptx L3 unc r tract | GCST90385219 | 1.17e-03 |
| 10432 | Extrapyramidal disease and abnormal movement disorders (PheCode 333) | GCST90475831 | 1.17e-03 |
| 10433 | Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers) | FING00000756 | 1.17e-03 |
| 10434 | CELA3A levels | GCST90468702 | 1.17e-03 |
| 10435 | TNFSF12 levels | GCST90470919 | 1.17e-03 |
| 10436 | GAS6 levels | GCST90469305 | 1.17e-03 |
| 10437 | LGALS7 or LGALS7B levels | GCST90469763 | 1.16e-03 |
| 10438 | Substance use, excluding alcohol | FING00001342 | 1.16e-03 |
| 10439 | MMP8/OLR1 ratio | GCST90315464 | 1.16e-03 |
| 10440 | TNFSF8 levels | GCST90470923 | 1.16e-03 |
| 10441 | Disorders of plasma protein metabolism (PheCode 270.3) | GCST90475709 | 1.16e-03 |
| 10442 | ALCAM/IL1RL2 ratio | GCST90313238 | 1.15e-03 |
| 10443 | HLA-E levels | GCST90469459 | 1.15e-03 |
| 10444 | Mononeuropathies of upper limb | Nerve, nerve root and plexus disorders | UKBB00000481 | 1.15e-03 |
| 10445 | Soy sauce liking | GCST90094844 | 1.15e-03 |
| 10446 | BST2 levels | GCST90468475 | 1.14e-03 |
| 10447 | F11R/PARK7 ratio | GCST90314723 | 1.14e-03 |
| 10448 | AXL/MSR1 ratio | GCST90313422 | 1.14e-03 |
| 10449 | AIF1 levels | GCST90468267 | 1.14e-03 |
| 10450 | Sarcoidosis | GCST90018698 | 1.14e-03 |
| 10451 | DTI autoptx L1 ifo r tract | GCST90385152 | 1.13e-03 |
| 10452 | MAPKAPK2 levels | GCST90469858 | 1.12e-03 |
| 10453 | KIRREL2/PLA2G1B ratio | GCST90315251 | 1.12e-03 |
| 10454 | Macular degeneration, wet (PheCode 362.22) | GCST90475852 | 1.11e-03 |
| 10455 | BCR/PLXNA4 ratio | GCST90313497 | 1.11e-03 |
| 10456 | T1 FreeSurfer aseg Left-Putamen | GCST90384145 | 1.11e-03 |
| 10457 | Psoriasis | GCST90019016 | 1.10e-03 |
| 10458 | IDS levels | GCST90469507 | 1.10e-03 |
| 10459 | Beans liking | GCST90094699 | 1.09e-03 |
| 10460 | NINJ1 levels | GCST90470049 | 1.09e-03 |
| 10461 | FTCD levels | GCST90469274 | 1.08e-03 |
| 10462 | Smoking and associated risk behaviours (confirmatory factor analysis Factor 6) | GCST90309341 | 1.08e-03 |
| 10463 | CAPG levels | GCST90468537 | 1.07e-03 |
| 10464 | Malignant neoplasm of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00000777 | 1.07e-03 |
| 10465 | Operation code - inguinal hernia repair | Operations | UKBB00000560 | 1.07e-03 |
| 10466 | LECT2 levels | GCST90469751 | 1.07e-03 |
| 10467 | lymphocyte (absolute count, maximum, inv-norm transformed) | GCST90475423 | 1.07e-03 |
| 10468 | Dermatitis | FING00000401 | 1.07e-03 |
| 10469 | NOS3 levels | GCST90470064 | 1.06e-03 |
| 10470 | Phosphatidylcholine levels | GCST90499248 | 1.06e-03 |
| 10471 | BACH1/NFATC1 ratio | GCST90313444 | 1.06e-03 |
| 10472 | LTBR levels | GCST90243176 | 1.06e-03 |
| 10473 | Takes medication for gout? | GCST90476382 | 1.06e-03 |
| 10474 | NFATC1/SPRY2 ratio | GCST90315539 | 1.06e-03 |
| 10475 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 1.06e-03 |
| 10476 | LRPAP1 levels | GCST90469800 | 1.06e-03 |
| 10477 | RAB27B levels | GCST90470405 | 1.05e-03 |
| 10478 | TGFBR2/TNFRSF1A ratio | GCST90315918 | 1.05e-03 |
| 10479 | Endometriosis diagnosis and infertility diagnosis occurring together | FING00000499 | 1.04e-03 |
| 10480 | PDGFB levels | GCST90470189 | 1.04e-03 |
| 10481 | CIAPIN1/PLA2G4A ratio | GCST90314065 | 1.04e-03 |
| 10482 | FKBP5/TBCC ratio | GCST90314849 | 1.04e-03 |
| 10483 | Myocardial infarction (PheCode 411.2) | GCST90043954 | 1.04e-03 |
| 10484 | IGSF8/VSIR ratio | GCST90315141 | 1.04e-03 |
| 10485 | LYZL2 levels | GCST90469833 | 1.04e-03 |
| 10486 | CNDP1/F9 ratio | GCST90314147 | 1.04e-03 |
| 10487 | Posterior thigh muscle fat infiltration percentage | GCST90267355 | 1.03e-03 |
| 10488 | Skin cancer | GCST90475575 | 1.03e-03 |
| 10489 | CLPS/PLA2G1B ratio | GCST90314140 | 1.03e-03 |
| 10490 | X-12095--N1-methyl-3-pyridone-4-carboxamide levels | GCST90243701 | 1.03e-03 |
| 10491 | CXCL5/SERPINE1 ratio | GCST90314354 | 1.03e-03 |
| 10492 | PLPBP levels | GCST90470260 | 1.02e-03 |
| 10493 | NT5C3A/PRDX5 ratio | GCST90315567 | 1.02e-03 |
| 10494 | Principal component-derived dietary pattern 40 | GCST90133045 | 1.02e-03 |
| 10495 | AKT1S1 levels | GCST90468276 | 1.02e-03 |
| 10496 | AMBN levels | GCST90468287 | 1.02e-03 |
| 10497 | RELT levels | GCST90470453 | 1.02e-03 |
| 10498 | CCN2/DKK1 ratio | GCST90313710 | 1.02e-03 |
| 10499 | CCL5/LAMA4 ratio | GCST90313703 | 1.01e-03 |
| 10500 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90501068 | 1.01e-03 |
| 10501 | LPP levels | GCST90469790 | 1.01e-03 |
| 10502 | Varicose veins | FING00001416 | 1.01e-03 |
| 10503 | PDLIM7 levels | GCST90470198 | 1.00e-03 |
| 10504 | FADD/GRAP2 ratio | GCST90314766 | 1.00e-03 |
| 10505 | MANF/PDGFB ratio | GCST90315360 | 9.98e-04 |
| 10506 | Omega-3 fatty acids to total fatty acids percentage | GCST90502463 | 9.96e-04 |
| 10507 | ANG levels | GCST90468307 | 9.95e-04 |
| 10508 | Phosphate levels (UKB data field 30810) | GCST90468094 | 9.92e-04 |
| 10509 | RIDA levels | GCST90470469 | 9.92e-04 |
| 10510 | COL18A1/RETN ratio | GCST90314170 | 9.86e-04 |
| 10511 | Papulosquamous disorders | FING00001144 | 9.84e-04 |
| 10512 | CPXM2 levels | GCST90468850 | 9.81e-04 |
| 10513 | Operative procedures - Primary total prosthetic replacement of knee joint using cement | Summary Operations | UKBB00000588 | 9.79e-04 |
| 10514 | Concentration of HDL particles | GCST90497406 | 9.77e-04 |
| 10515 | Citrate levels | GCST90497200 | 9.77e-04 |
| 10516 | Hashimoto thyroiditis | GCST90018635 | 9.77e-04 |
| 10517 | Triglyceride to phosphoglyceride ratio | GCST90454483 | 9.69e-04 |
| 10518 | CD7 levels | GCST90468649 | 9.59e-04 |
| 10519 | GCNT1 levels | GCST90469319 | 9.58e-04 |
| 10520 | SORCS2 levels | GCST90470708 | 9.52e-04 |
| 10521 | CCL5/CXCL3 ratio | GCST90313700 | 9.46e-04 |
| 10522 | FEN1 levels | GCST90469213 | 9.46e-04 |
| 10523 | SMNDC1 levels | GCST90470681 | 9.43e-04 |
| 10524 | IMMT levels | GCST90469609 | 9.43e-04 |
| 10525 | MSRA/PRDX5 ratio | GCST90315497 | 9.40e-04 |
| 10526 | Phospholipids in medium HDL | GCST90498641 | 9.39e-04 |
| 10527 | TNFRSF8 levels | GCST90470915 | 9.38e-04 |
| 10528 | Reimbursement for rheumatic diseases | FING00001247 | 9.36e-04 |
| 10529 | Hyperthyroidism | GCST90319319 | 9.31e-04 |
| 10530 | UBXN1 levels | GCST90471004 | 9.31e-04 |
| 10531 | Total lipids in small HDL (UKB data field 23573) | GCST90269670 | 9.31e-04 |
| 10532 | APP/TMSB10 ratio | GCST90313332 | 9.23e-04 |
| 10533 | KLRB1/KLRD1 ratio | GCST90315260 | 9.22e-04 |
| 10534 | CD63/EDAR ratio | GCST90313864 | 9.19e-04 |
| 10535 | DTI autoptx MD fmi tract | GCST90385231 | 9.16e-04 |
| 10536 | ARHGAP1/SPARC ratio | GCST90313344 | 9.14e-04 |
| 10537 | B4GALT1/IFNGR1 ratio | GCST90313430 | 9.14e-04 |
| 10538 | Pneumonia | GCST90018681 | 9.05e-04 |
| 10539 | LBP levels | GCST90469743 | 9.05e-04 |
| 10540 | SERPINB1/SERPINB6 ratio | GCST90315826 | 8.99e-04 |
| 10541 | Eosinophill percentage | Blood count | UKBB00000207 | 8.98e-04 |
| 10542 | CAMSAP1 levels | GCST90468535 | 8.95e-04 |
| 10543 | APBB1IP/NADK ratio | GCST90313298 | 8.95e-04 |
| 10544 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 8.94e-04 |
| 10545 | Athlete's foot (PheCode 110.12) | GCST90475563 | 8.92e-04 |
| 10546 | CA13/TYMP ratio | GCST90313568 | 8.91e-04 |
| 10547 | LAYN/VWC2 ratio | GCST90315293 | 8.91e-04 |
| 10548 | Histidine levels | GCST90497479 | 8.90e-04 |
| 10549 | aparc-a2009s lh thickness S-postcentral | GCST90003669 | 8.90e-04 |
| 10550 | EEF1D levels | GCST90469075 | 8.87e-04 |
| 10551 | CLEC1B/ITGB5 ratio | GCST90314094 | 8.86e-04 |
| 10552 | IDP dMRI TBSS ISOVF Genu of corpus callosum | GCST90004479 | 8.85e-04 |
| 10553 | Breast cancer [female] | neoplasms | UKBB00000108 | 8.80e-04 |
| 10554 | AK1/NSFL1C ratio | GCST90313224 | 8.78e-04 |
| 10555 | Disorders of iris and ciliary body (PheCode 379.5) | GCST90475899 | 8.73e-04 |
| 10556 | FCRL1/TREML2 ratio | GCST90314797 | 8.70e-04 |
| 10557 | MMP9/PLAUR ratio | GCST90315470 | 8.70e-04 |
| 10558 | PTN levels | GCST90470374 | 8.67e-04 |
| 10559 | Eosinophil percentage of white cells | GCST90002382 | 8.66e-04 |
| 10560 | DOK2/LACTB2 ratio | GCST90314532 | 8.63e-04 |
| 10561 | GPKOW/PXN ratio | GCST90314978 | 8.60e-04 |
| 10562 | NTN4 levels | GCST90242049 | 8.59e-04 |
| 10563 | KLF4 levels | GCST90469694 | 8.57e-04 |
| 10564 | N-acetylphenylalanine levels | GCST90200677 | 8.55e-04 |
| 10565 | Anal and rectal conditions | digestive | UKBB00000029 | 8.53e-04 |
| 10566 | PLXNB2 levels | GCST90470266 | 8.52e-04 |
| 10567 | T1 FreeSurfer BA rh BA4p exvivo area | GCST90385552 | 8.49e-04 |
| 10568 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 128) | GCST90320691 | 8.49e-04 |
| 10569 | SNAP23/ZBTB16 ratio | GCST90315858 | 8.43e-04 |
| 10570 | CNTNAP2/DPP6 ratio | GCST90314168 | 8.43e-04 |
| 10571 | PGF levels | GCST90470218 | 8.42e-04 |
| 10572 | FAM3B/FUT3_FUT5 ratio | GCST90314777 | 8.40e-04 |
| 10573 | BCR/GOPC ratio | GCST90313491 | 8.39e-04 |
| 10574 | NCF2 levels | GCST90470006 | 8.35e-04 |
| 10575 | Plasma lysine levels in chronic kidney disease | GCST90265459 | 8.31e-04 |
| 10576 | FKBP1B/TGFB1 ratio | GCST90314836 | 8.27e-04 |
| 10577 | Psoriasis vulgaris | FING00001224 | 8.25e-04 |
| 10578 | Degenerative skin conditions and other dermatoses (PheCode 702) | GCST90476202 | 8.25e-04 |
| 10579 | DKK1/PDGFA ratio | GCST90314475 | 8.25e-04 |
| 10580 | IL12B levels | GCST90274798 | 8.23e-04 |
| 10581 | Operation code - tonsillectomy +/- adenoids | Operations | UKBB00000567 | 8.16e-04 |
| 10582 | Myocardial fractal dimension (slice 7) | GCST90000293 | 8.15e-04 |
| 10583 | Thyrotoxicosis with diffuse goitre | FING00001361 | 8.14e-04 |
| 10584 | Suggestive for eosinophilic asthma | FING00001344 | 8.12e-04 |
| 10585 | Hair colour (natural, before greying) - Dark brown | Sun exposure | UKBB00000297 | 8.11e-04 |
| 10586 | APP/CD40LG ratio | GCST90313319 | 8.06e-04 |
| 10587 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 118) | GCST90320681 | 8.06e-04 |
| 10588 | Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI) | GCST90267573 | 7.99e-04 |
| 10589 | Takes medication for circulatory problem? | GCST90475218 | 7.98e-04 |
| 10590 | Alkylphosphatidylcholine (O-34:1) levels | GCST90025551 | 7.97e-04 |
| 10591 | GP2/LGALS4 ratio | GCST90314960 | 7.96e-04 |
| 10592 | Ovarian cancer-related tumor marker CA 125 levels | GCST90012078 | 7.95e-04 |
| 10593 | SPINT1 levels | GCST90470727 | 7.95e-04 |
| 10594 | TGFBI levels | GCST90470845 | 7.93e-04 |
| 10595 | CD46/SELP ratio | GCST90313834 | 7.92e-04 |
| 10596 | PPP1R12A/SKAP2 ratio | GCST90315710 | 7.92e-04 |
| 10597 | EIF4B/IPCEF1 ratio | GCST90314622 | 7.91e-04 |
| 10598 | Cholesteryl esters in small HDL (UKB data field 23576) | GCST90269673 | 7.89e-04 |
| 10599 | Benign neoplasm of eye, uveal (PheCode 224.1) | GCST90475629 | 7.87e-04 |
| 10600 | SORT1/VSIR ratio | GCST90315870 | 7.85e-04 |
| 10601 | Right-hemisphere visual network to hippocampus white-matter structural connectivity | GCST90302785 | 7.85e-04 |
| 10602 | Microalbumin in urine | Urine assays | UKBB00000467 | 7.85e-04 |
| 10603 | SDCCAG8 levels | GCST90470560 | 7.80e-04 |
| 10604 | PLAT levels | GCST90470250 | 7.78e-04 |
| 10605 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T11 | ECGA000011 | 7.75e-04 |
| 10606 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502399 | 7.73e-04 |
| 10607 | Other non-epithelial cancer of skin (PheCode 172.2) | GCST90475580 | 7.67e-04 |
| 10608 | MGAT2 levels | GCST90089560 | 7.66e-04 |
| 10609 | Seborrheic keratosis (PheCode 702.2) | GCST90476206 | 7.66e-04 |
| 10610 | CCL15/CCL23 ratio | GCST90313681 | 7.63e-04 |
| 10611 | Left-hemisphere dorsal attention network to putamen white-matter structural connectivity | GCST90302703 | 7.60e-04 |
| 10612 | Malignant neoplasm of rectum, excluding all cancers (controls excluding all cancers) | FING00000771 | 7.58e-04 |
| 10613 | RABGAP1L levels | GCST90470416 | 7.57e-04 |
| 10614 | Blood cell traits latent factor 10 (platelet) | GCST90559252 | 7.57e-04 |
| 10615 | Hair colour (natural, before greying) - Light brown | Sun exposure | UKBB00000298 | 7.56e-04 |
| 10616 | Docosahexaenoic acid to total fatty acids percentage | GCST90501999 | 7.50e-04 |
| 10617 | RELL1 levels | GCST90242625 | 7.49e-04 |
| 10618 | IDP dMRI TBSS MD Pontine crossing tract | GCST90004028 | 7.48e-04 |
| 10619 | IDP dMRI TBSS L3 Posterior limb of internal capsule R | GCST90004189 | 7.44e-04 |
| 10620 | NECTIN4/TGFBR2 ratio | GCST90315535 | 7.37e-04 |
| 10621 | VPS53 levels | GCST90471048 | 7.36e-04 |
| 10622 | Right molecular layer hippocampal volume (body) | GCST90267975 | 7.36e-04 |
| 10623 | F2R/TMSB10 ratio | GCST90314738 | 7.34e-04 |
| 10624 | EPO levels | GCST90469136 | 7.34e-04 |
| 10625 | CSTB levels | GCST90012006 | 7.33e-04 |
| 10626 | Plasma 11beta-hydroxyandrosterone glucuronide levels in chronic kidney disease | GCST90264321 | 7.32e-04 |
| 10627 | HippSubfield lh volume subiculum-body | GCST90002669 | 7.26e-04 |
| 10628 | Breathing problems responsible for leaving job | Employment history | UKBB00000112 | 7.23e-04 |
| 10629 | PLIN1 levels | GCST90470258 | 7.22e-04 |
| 10630 | LAT/SPARC ratio | GCST90315288 | 7.22e-04 |
| 10631 | Curry liking | GCST90094750 | 7.21e-04 |
| 10632 | SNAP29/SNX9 ratio | GCST90315859 | 7.20e-04 |
| 10633 | AHNAK2 levels | GCST90468260 | 7.20e-04 |
| 10634 | SLAMF1 levels | GCST90470649 | 7.18e-04 |
| 10635 | NECTIN4/SPINK5 ratio | GCST90315534 | 7.16e-04 |
| 10636 | ARHGEF1 levels | GCST90468359 | 7.16e-04 |
| 10637 | Nervonoylcarnitine (C24:1) levels | GCST90200143 | 7.14e-04 |
| 10638 | CDH5/PCDH17 ratio | GCST90313958 | 7.12e-04 |
| 10639 | ATP5IF1/F2R ratio | GCST90313384 | 7.06e-04 |
| 10640 | USO1 levels | GCST90471018 | 7.06e-04 |
| 10641 | Triacylglycerol_50:3_[M+NH4]1+ levels | GCST90060468 | 7.06e-04 |
| 10642 | Nasal polyp | FING00000858 | 7.03e-04 |
| 10643 | NT5C levels | GCST90470092 | 7.03e-04 |
| 10644 | CEP43/PLXNB3 ratio | GCST90314020 | 6.96e-04 |
| 10645 | SMAD1 levels | GCST90470675 | 6.93e-04 |
| 10646 | Takes medication for Glaucoma? | GCST90475384 | 6.92e-04 |
| 10647 | Ulcerative enterocolitis | FING00001391 | 6.92e-04 |
| 10648 | SERPINA3 levels | GCST90470583 | 6.91e-04 |
| 10649 | CASP3/SERPINE1 ratio | GCST90313643 | 6.90e-04 |
| 10650 | CD28 levels | GCST90468616 | 6.85e-04 |
| 10651 | GRAP2/LACTB2 ratio | GCST90314980 | 6.83e-04 |
| 10652 | CDC37/SNX9 ratio | GCST90313936 | 6.83e-04 |
| 10653 | Asthma/COPD (KELA code 203) | FING00000121 | 6.83e-04 |
| 10654 | Calculus of ureter (PheCode 594.3) | GCST90476147 | 6.79e-04 |
| 10655 | CRELD2/ERP44 ratio | GCST90314253 | 6.79e-04 |
| 10656 | CLEC4G levels | GCST90468774 | 6.78e-04 |
| 10657 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 111) | GCST90320930 | 6.77e-04 |
| 10658 | CTRC/KIRREL2 ratio | GCST90314309 | 6.72e-04 |
| 10659 | PEAR1/TREML2 ratio | GCST90315645 | 6.67e-04 |
| 10660 | MED18 levels | GCST90469880 | 6.66e-04 |
| 10661 | FABP1/SULT2A1 ratio | GCST90314755 | 6.65e-04 |
| 10662 | CNTN1 levels | GCST90468803 | 6.61e-04 |
| 10663 | B2M levels | GCST90468409 | 6.60e-04 |
| 10664 | PAFAH1B3 levels | GCST90470145 | 6.60e-04 |
| 10665 | CD74 levels | GCST90468647 | 6.59e-04 |
| 10666 | ATF6 levels | GCST90240816 | 6.58e-04 |
| 10667 | PI3 levels | GCST90470230 | 6.58e-04 |
| 10668 | Asthma | GCST90086047 | 6.57e-04 |
| 10669 | APP/LAMA4 ratio | GCST90313325 | 6.57e-04 |
| 10670 | TBC1D5 levels | GCST90470811 | 6.56e-04 |
| 10671 | Pregnenetriol disulfate levels | GCST90200238 | 6.55e-04 |
| 10672 | Acne | FING00000010 | 6.54e-04 |
| 10673 | CELA3A/CTRB1 ratio | GCST90314011 | 6.53e-04 |
| 10674 | DKK1/VTA1 ratio | GCST90314485 | 6.52e-04 |
| 10675 | Other serious medical condition/disability diagnosed by doctor | Medical conditions | UKBB00000619 | 6.51e-04 |
| 10676 | IL15/NCR1 ratio | GCST90315150 | 6.51e-04 |
| 10677 | DXO levels | GCST90469055 | 6.49e-04 |
| 10678 | Neutrophil percentage of granulocytes | GCST004623 | 6.47e-04 |
| 10679 | Skin cancer | GCST90475189 | 6.47e-04 |
| 10680 | Chronic sinusitis | FING00000298 | 6.44e-04 |
| 10681 | HSPA1A/MGLL ratio | GCST90315083 | 6.42e-04 |
| 10682 | GM3 ganglioside (d18:1/24:0) levels | GCST90025340 | 6.42e-04 |
| 10683 | FCGR2B/NOS3 ratio | GCST90314794 | 6.41e-04 |
| 10684 | CXCL9 levels | GCST90274784 | 6.40e-04 |
| 10685 | CHMP6 levels | GCST90468747 | 6.39e-04 |
| 10686 | CCL8 levels | GCST90422346 | 6.38e-04 |
| 10687 | C4BPB/ENTPD5 ratio | GCST90313556 | 6.35e-04 |
| 10688 | CNDP1/EGFR ratio | GCST90314146 | 6.34e-04 |
| 10689 | HVEM on Terminally Differentiated CD4+ T cell | GCST90001879 | 6.34e-04 |
| 10690 | PIK3AP1 levels | GCST90470233 | 6.32e-04 |
| 10691 | Medication use (diuretics) | GCST90018765 | 6.29e-04 |
| 10692 | CCL17/PDGFB ratio | GCST90313688 | 6.27e-04 |
| 10693 | MANF/SDC4 ratio | GCST90315367 | 6.26e-04 |
| 10694 | KIR3DL1 levels | GCST90469687 | 6.24e-04 |
| 10695 | GZMB levels | GCST90469424 | 6.23e-04 |
| 10696 | Concentration of small HDL particles | GCST90092951 | 6.23e-04 |
| 10697 | Cysteine-glutathione disulfide levels | GCST90199784 | 6.20e-04 |
| 10698 | Autoimmune diseases | FING00000131 | 6.19e-04 |
| 10699 | TNFRSF4/TNFRSF9 ratio | GCST90315939 | 6.18e-04 |
| 10700 | RAB10 levels | GCST90470403 | 6.17e-04 |
| 10701 | FCRL1 levels | GCST90469205 | 6.14e-04 |
| 10702 | IGF1 levels | UKBB00000337 | 6.13e-04 |
| 10703 | DNAJA2/SCAMP3 ratio | GCST90314507 | 6.12e-04 |
| 10704 | Doctor diagnosed hayfever or allergic rhinitis | Medical information | UKBB00000192 | 6.12e-04 |
| 10705 | LGALS3 levels | GCST90012009 | 6.09e-04 |
| 10706 | IDP dMRI TBSS MO Medial lemniscus R | GCST90003960 | 6.06e-04 |
| 10707 | WFIKKN2 levels | GCST90422127 | 6.04e-04 |
| 10708 | SKAP2/VSIR ratio | GCST90315849 | 6.03e-04 |
| 10709 | rfMRI amplitudes (ICA100 node 44) | GCST90004632 | 6.02e-04 |
| 10710 | Asthma and allergy | FING00000115 | 6.00e-04 |
| 10711 | Psoriasis (vulgaris), strict definition | FING00001223 | 5.98e-04 |
| 10712 | SAMD9L levels | GCST90470524 | 5.98e-04 |
| 10713 | TNFSF10 levels | GCST90470917 | 5.95e-04 |
| 10714 | CERT/MAX ratio | GCST90314028 | 5.95e-04 |
| 10715 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T443 | ECGU000443 | 5.94e-04 |
| 10716 | TNFSF10 levels | GCST90012011 | 5.93e-04 |
| 10717 | FHIT/PARK7 ratio | GCST90314821 | 5.91e-04 |
| 10718 | PPM1F levels | GCST90470297 | 5.90e-04 |
| 10719 | Lysophosphatidylcholine (24:0) [sn1] levels | GCST90025425 | 5.90e-04 |
| 10720 | ESYT2 levels | GCST90469156 | 5.90e-04 |
| 10721 | CNST/PRKAR1A ratio | GCST90314161 | 5.86e-04 |
| 10722 | Pollen allergy | FING00001176 | 5.82e-04 |
| 10723 | Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74) | GCST90668518 | 5.81e-04 |
| 10724 | Disorders of sclera, cornea, iris and ciliary body | FING00000458 | 5.79e-04 |
| 10725 | MCFD2/VSIR ratio | GCST90315411 | 5.77e-04 |
| 10726 | SERPINA7 levels | GCST90470587 | 5.75e-04 |
| 10727 | METAP1D/VASH1 ratio | GCST90315429 | 5.73e-04 |
| 10728 | KIAA2013 levels | GCST90469679 | 5.71e-04 |
| 10729 | Lichen ruber planus, wide definition including periferal and oral lichen planus | FING00000722 | 5.70e-04 |
| 10730 | IGLC2 levels | GCST90469536 | 5.70e-04 |
| 10731 | CD46/TNFRSF14 ratio | GCST90313838 | 5.68e-04 |
| 10732 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 5.68e-04 |
| 10733 | Coeliac disease | FING00000312 | 5.68e-04 |
| 10734 | ATP5IF1/DECR1 ratio | GCST90313382 | 5.65e-04 |
| 10735 | HippSubfield rh volume hippocampal-fissure | GCST90002694 | 5.64e-04 |
| 10736 | TBL1X levels | GCST90470815 | 5.63e-04 |
| 10737 | DPEP2 levels | GCST90469031 | 5.61e-04 |
| 10738 | PARK7 levels | GCST90470159 | 5.58e-04 |
| 10739 | SDC4/SELP ratio | GCST90315817 | 5.57e-04 |
| 10740 | Psoriasis (PheCode 696.4) | GCST90476187 | 5.56e-04 |
| 10741 | CNTNAP4 levels | GCST90468809 | 5.56e-04 |
| 10742 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 5.56e-04 |
| 10743 | NFKB1 levels | GCST90470037 | 5.55e-04 |
| 10744 | CRYBB1 levels | GCST90468874 | 5.55e-04 |
| 10745 | PRKAR1A/SNAP23 ratio | GCST90315728 | 5.54e-04 |
| 10746 | Thyroid stimulating hormone levels | GCST90319321 | 5.54e-04 |
| 10747 | Selective deficiency of immunoglobulin G [IgG] subclasses | FING00001288 | 5.52e-04 |
| 10748 | CD300C levels | GCST90468620 | 5.50e-04 |
| 10749 | Malignant neoplasm of brain, excluding all cancers (controls excluding all cancers) | FING00000752 | 5.49e-04 |
| 10750 | EPS8L2/LGALS4 ratio | GCST90314685 | 5.48e-04 |
| 10751 | ACYP1 levels | GCST90468214 | 5.47e-04 |
| 10752 | PDCD1 levels | GCST90470181 | 5.45e-04 |
| 10753 | Subclinical hypothyroidism in pregnancy | GCST90435197 | 5.44e-04 |
| 10754 | CXCL10/CXCL11 ratio | GCST90314330 | 5.43e-04 |
| 10755 | ESAM/FUT8 ratio | GCST90314711 | 5.41e-04 |
| 10756 | severe traumatic brain injury, does not include concussion | FING00001300 | 5.41e-04 |
| 10757 | CASP3/MESD ratio | GCST90313636 | 5.40e-04 |
| 10758 | F-lentils/beans liking (derived food-liking factor) | GCST90094793 | 5.38e-04 |
| 10759 | CLEC1B/LBR ratio | GCST90314095 | 5.38e-04 |
| 10760 | First line medication for Crohn's disease | FING00000544 | 5.37e-04 |
| 10761 | SPARC/ZBTB16 ratio | GCST90315875 | 5.34e-04 |
| 10762 | Benign neoplasm of eye (PheCode 224) | GCST90475626 | 5.34e-04 |
| 10763 | ESAM/TNFRSF14 ratio | GCST90314720 | 5.30e-04 |
| 10764 | Actinic keratosis | FING00000013 | 5.27e-04 |
| 10765 | CRADD/HSPA1A ratio | GCST90314239 | 5.25e-04 |
| 10766 | AmygNuclei lh volume Medial-nucleus | GCST90002653 | 5.24e-04 |
| 10767 | NBL1 levels | GCST90470001 | 5.22e-04 |
| 10768 | PRSS22 levels | GCST90470341 | 5.19e-04 |
| 10769 | Liver fat | GCST90566817 | 5.19e-04 |
| 10770 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 5.18e-04 |
| 10771 | AARSD1/PIK3AP1 ratio | GCST90313129 | 5.18e-04 |
| 10772 | Omega-3 fatty acids to total fatty acids percentage | GCST90502090 | 5.17e-04 |
| 10773 | HBEGF levels | GCST90241392 | 5.14e-04 |
| 10774 | Other hammer toe(s) (acquired) | FING00001054 | 5.12e-04 |
| 10775 | AXIN1/BACH1 ratio | GCST90313400 | 5.09e-04 |
| 10776 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 5) | GCST90320568 | 5.08e-04 |
| 10777 | FOLR3 levels | GCST90469261 | 5.07e-04 |
| 10778 | Sacroiliitis, not elsewhere classified | FING00001273 | 5.07e-04 |
| 10779 | Prescriptions - albuterol | beta2-agonist,bronchodilator,asthma | UKBB00000658 | 5.06e-04 |
| 10780 | Prescriptions - beta2-agonist|bronchodilator|asthma | UKBB00000670 | 5.06e-04 |
| 10781 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 5.06e-04 |
| 10782 | MMP10 levels | GCST90012050 | 5.06e-04 |
| 10783 | SMPD1/SMPDL3A ratio | GCST90315854 | 5.06e-04 |
| 10784 | eosinophil (fraction, maximum, inv-norm transformed) | GCST90475297 | 5.04e-04 |
| 10785 | PDGFB levels | GCST90012016 | 5.03e-04 |
| 10786 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 5.01e-04 |
| 10787 | CDH6/NTRK2 ratio | GCST90313962 | 5.01e-04 |
| 10788 | AmygNuclei rh volume Whole-amygdala | GCST90002667 | 5.00e-04 |
| 10789 | IGF2R/LGMN ratio | GCST90315131 | 4.98e-04 |
| 10790 | Allergic rhinitis | FING00000071 | 4.97e-04 |
| 10791 | CLEC4D/HGF ratio | GCST90314110 | 4.97e-04 |
| 10792 | Acute upper respiratory infections | FING00000034 | 4.95e-04 |
| 10793 | Glycated haemoglobin (HbA1c) | Blood biochemistry | UKBB00000289 | 4.94e-04 |
| 10794 | Alkenylphosphatidylethanolamine (P-20:0/18:2) levels | GCST90025683 | 4.94e-04 |
| 10795 | HSD11B1 levels | GCST90469482 | 4.92e-04 |
| 10796 | Eosinophil percentage of white cells | GCST004600 | 4.92e-04 |
| 10797 | NCR1 levels | GCST90090153 | 4.91e-04 |
| 10798 | ITGB1BP2 levels | GCST90012058 | 4.89e-04 |
| 10799 | Ceramide (d18:2/24:0) levels | GCST90024055 | 4.89e-04 |
| 10800 | DOK2/PPP1R2 ratio | GCST90314537 | 4.89e-04 |
| 10801 | CCN2/ENO2 ratio | GCST90313712 | 4.88e-04 |
| 10802 | VTI1A levels | GCST90471060 | 4.87e-04 |
| 10803 | Thyroxine levels | GCST90200293 | 4.87e-04 |
| 10804 | BTN2A1/SPINT2 ratio | GCST90313550 | 4.86e-04 |
| 10805 | Second line medication for Crohn's disease | FING00001284 | 4.85e-04 |
| 10806 | TGFB1 levels | GCST90274818 | 4.84e-04 |
| 10807 | CD69/SNAP23 ratio | GCST90313886 | 4.83e-04 |
| 10808 | Takes medication for peripheral vascular disease? | GCST90475220 | 4.83e-04 |
| 10809 | Hypothyroidism NOS (PheCode 244.4) | GCST90475653 | 4.83e-04 |
| 10810 | ISM1 levels | GCST90469630 | 4.82e-04 |
| 10811 | Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583) | GCST90269680 | 4.78e-04 |
| 10812 | Left-hemisphere control network to putamen white-matter structural connectivity | GCST90302754 | 4.78e-04 |
| 10813 | Eosinophil percentage of granulocytes | GCST004617 | 4.78e-04 |
| 10814 | PEBP1 levels | GCST90470205 | 4.77e-04 |
| 10815 | LAT/PDGFA ratio | GCST90315285 | 4.76e-04 |
| 10816 | PDCD1/TNFRSF8 ratio | GCST90315610 | 4.76e-04 |
| 10817 | GFRA1/SPON2 ratio | GCST90314923 | 4.75e-04 |
| 10818 | CPB1/REG1B ratio | GCST90314213 | 4.75e-04 |
| 10819 | Inguinal hernia, bilateral | FING00000682 | 4.74e-04 |
| 10820 | BCR levels | GCST90468436 | 4.74e-04 |
| 10821 | Right-hemisphere dorsal attention network to thalamus white-matter structural connectivity | GCST90302806 | 4.73e-04 |
| 10822 | NAGPA levels | GCST90469996 | 4.73e-04 |
| 10823 | LUZP2 levels | GCST90469819 | 4.72e-04 |
| 10824 | Generalized epilepsy | FING00000567 | 4.72e-04 |
| 10825 | GZMH levels | GCST90469425 | 4.72e-04 |
| 10826 | LAIR1 levels | GCST90469728 | 4.70e-04 |
| 10827 | SPINK1 levels | GCST90470721 | 4.68e-04 |
| 10828 | PLA2G4A/SDC4 ratio | GCST90315668 | 4.68e-04 |
| 10829 | F-sauces liking (derived food-liking factor) | GCST90094831 | 4.68e-04 |
| 10830 | GP6/TMSB10 ratio | GCST90314975 | 4.68e-04 |
| 10831 | Angina pectoris | Ischaemic heart diseases | UKBB00000031 | 4.67e-04 |
| 10832 | Primary open angle glaucoma (PheCode 365.11) | GCST90475875 | 4.66e-04 |
| 10833 | CREG1/GUSB ratio | GCST90314249 | 4.65e-04 |
| 10834 | SCRG1 levels | GCST90470554 | 4.65e-04 |
| 10835 | DEFA1_DEFA1B/PTGDS ratio | GCST90314455 | 4.64e-04 |
| 10836 | Benign neoplasm: Rectum | FING00000196 | 4.63e-04 |
| 10837 | Urinary ethanolamine to urinary creatinine ratio | GCST90451717 | 4.60e-04 |
| 10838 | Hayfever | GCST90468131 | 4.57e-04 |
| 10839 | Rheumatoid arthritis | FING00001267 | 4.57e-04 |
| 10840 | HLAE/IL15 ratio | GCST90315061 | 4.55e-04 |
| 10841 | Basal cell carcinoma | GCST90013410 | 4.55e-04 |
| 10842 | Eosinophil count | GCST004606 | 4.55e-04 |
| 10843 | Left-hemisphere control network to amygdala white-matter structural connectivity | GCST90302757 | 4.52e-04 |
| 10844 | TPSAB1 levels | GCST90470951 | 4.52e-04 |
| 10845 | C4BPB levels | GCST90468499 | 4.51e-04 |
| 10846 | CREG1/SMPDL3A ratio | GCST90314252 | 4.50e-04 |
| 10847 | Biological Sibling: Asthma | GCST90476372 | 4.50e-04 |
| 10848 | PNMA1 levels | GCST90470276 | 4.50e-04 |
| 10849 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 4.49e-04 |
| 10850 | KIR2DL2 levels | GCST90469684 | 4.49e-04 |
| 10851 | CTSO/IGF2R ratio | GCST90314317 | 4.48e-04 |
| 10852 | Retrobulbar neuritis in diseases classified elsewhere | FING00001265 | 4.48e-04 |
| 10853 | IRAK1/NFATC1 ratio | GCST90315194 | 4.48e-04 |
| 10854 | GZMA/GZMB ratio | GCST90315007 | 4.47e-04 |
| 10855 | MAP4K5/TBCC ratio | GCST90315385 | 4.47e-04 |
| 10856 | CTSF/SMPDL3A ratio | GCST90314316 | 4.43e-04 |
| 10857 | CD300E/CD59 ratio | GCST90313794 | 4.42e-04 |
| 10858 | Alkylphosphatidylcholine (O-34:1) levels | GCST90024925 | 4.41e-04 |
| 10859 | F11R/TMSB10 ratio | GCST90314729 | 4.40e-04 |
| 10860 | Light-intensity physical activity duration | GCST90061421 | 4.38e-04 |
| 10861 | Eosinophil count | GCST90002381 | 4.38e-04 |
| 10862 | ANGPTL4 levels | GCST90468305 | 4.38e-04 |
| 10863 | ESM1 levels | GCST90012068 | 4.37e-04 |
| 10864 | Histidine levels (UKB data field 23463) | GCST90269560 | 4.36e-04 |
| 10865 | NAGA levels | GCST90469994 | 4.36e-04 |
| 10866 | Biological Grandparent (maternal): Alzheimer's / Other Dementia | GCST90475484 | 4.35e-04 |
| 10867 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 4.35e-04 |
| 10868 | HippSubfield lh volume subiculum-head | GCST90002671 | 4.34e-04 |
| 10869 | SCARA5/TGFBI ratio | GCST90315809 | 4.33e-04 |
| 10870 | XG levels | GCST90471082 | 4.31e-04 |
| 10871 | PCDH17 levels | GCST90470169 | 4.25e-04 |
| 10872 | DTI autoptx MD unc r tract | GCST90385246 | 4.25e-04 |
| 10873 | FOLR3/KLK8 ratio | GCST90314868 | 4.24e-04 |
| 10874 | Eosinophil count | GCST90002298 | 4.23e-04 |
| 10875 | Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592) | GCST90269689 | 4.23e-04 |
| 10876 | BTN2A1/IFNGR1 ratio | GCST90313543 | 4.22e-04 |
| 10877 | ATP5IF1/FXN ratio | GCST90313386 | 4.22e-04 |
| 10878 | TNIP1 levels | GCST90470925 | 4.21e-04 |
| 10879 | BTN2A1 levels | GCST90468480 | 4.20e-04 |
| 10880 | ITGB1/SELP ratio | GCST90315230 | 4.20e-04 |
| 10881 | CXCL11 levels | GCST90274781 | 4.18e-04 |
| 10882 | Principal component-derived dietary pattern 52 | GCST90133056 | 4.18e-04 |
| 10883 | Phosphate | Blood biochemistry | UKBB00000644 | 4.18e-04 |
| 10884 | DKK1 levels | GCST90012060 | 4.18e-04 |
| 10885 | PTH1R levels | GCST90470371 | 4.17e-04 |
| 10886 | SPON2 levels | GCST90470732 | 4.17e-04 |
| 10887 | CALCOCO1/PDLIM7 ratio | GCST90313607 | 4.17e-04 |
| 10888 | FUS levels | GCST90469278 | 4.16e-04 |
| 10889 | FABP6 levels | GCST90469178 | 4.15e-04 |
| 10890 | CXCL5/SDC4 ratio | GCST90314353 | 4.15e-04 |
| 10891 | Other haemoglobinopathies | FING00001053 | 4.15e-04 |
| 10892 | DDC levels | GCST90468967 | 4.13e-04 |
| 10893 | Primary biliary cholangitis (PBC) | FING00001211 | 4.13e-04 |
| 10894 | TPM2 levels | GCST90243122 | 4.12e-04 |
| 10895 | SVEP1 levels | GCST90242928 | 4.11e-04 |
| 10896 | FAM3C levels | GCST90469187 | 4.10e-04 |
| 10897 | CD80 levels | GCST90468650 | 4.10e-04 |
| 10898 | OLR1/PLAUR ratio | GCST90315584 | 4.08e-04 |
| 10899 | FABP2 levels | GCST90469174 | 4.08e-04 |
| 10900 | FURIN/PLA2G15 ratio | GCST90314887 | 4.08e-04 |
| 10901 | Endometriosis ASRM stages 3,4 | FING00000498 | 4.08e-04 |
| 10902 | ZFYVE19 levels | GCST90471098 | 4.07e-04 |
| 10903 | CNST levels | GCST90468801 | 4.04e-04 |
| 10904 | Phosphatidylcholine levels | GCST90092937 | 4.04e-04 |
| 10905 | ADH1B levels | GCST90468243 | 4.04e-04 |
| 10906 | DIABLO/PRKAR1A ratio | GCST90314469 | 4.01e-04 |
| 10907 | ENTPD5 levels | GCST90469121 | 4.01e-04 |
| 10908 | VASP levels | GCST90471028 | 4.00e-04 |
| 10909 | Tryptophan betaine levels | GCST90199819 | 4.00e-04 |
| 10910 | CD83/TNFRSF4 ratio | GCST90313907 | 3.99e-04 |
| 10911 | EREG/HBEGF ratio | GCST90314702 | 3.99e-04 |
| 10912 | INPP1 levels | GCST90469616 | 3.98e-04 |
| 10913 | RGMA/RGMB ratio | GCST90315769 | 3.97e-04 |
| 10914 | F3/GFRA1 ratio | GCST90314741 | 3.95e-04 |
| 10915 | TNFRSF11B levels | GCST90243158 | 3.94e-04 |
| 10916 | CST6/GAL ratio | GCST90314302 | 3.94e-04 |
| 10917 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T447 | ECGU000447 | 3.94e-04 |
| 10918 | ARHGAP1 levels | GCST90468352 | 3.91e-04 |
| 10919 | Rheumatoid arthritis and other inflammatory (PheCode 714) | GCST90476228 | 3.90e-04 |
| 10920 | CEP43 levels | GCST90468715 | 3.89e-04 |
| 10921 | Spondylosis without myelopathy (PheCode 721.1) | GCST90476236 | 3.89e-04 |
| 10922 | CCN3 levels | GCST90242492 | 3.89e-04 |
| 10923 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 3.87e-04 |
| 10924 | Other contact dermatitis | FING00000990 | 3.85e-04 |
| 10925 | MDH1 levels | GCST90469876 | 3.85e-04 |
| 10926 | Other disorders of fluid, electrolyte and acid-base balance | FING00001027 | 3.82e-04 |
| 10927 | CFI levels | GCST90240782 | 3.81e-04 |
| 10928 | TNFRSF1A/TNFRSF1B ratio | GCST90315937 | 3.80e-04 |
| 10929 | Hyperthyroidism | GCST90468136 | 3.79e-04 |
| 10930 | VPS37A levels | GCST90471046 | 3.78e-04 |
| 10931 | EGFR/MEGF9 ratio | GCST90314614 | 3.78e-04 |
| 10932 | CX3CL1/DSG2 ratio | GCST90314323 | 3.77e-04 |
| 10933 | DAAM1 levels | GCST90468941 | 3.77e-04 |
| 10934 | PLIN3/VSIR ratio | GCST90315679 | 3.75e-04 |
| 10935 | Mineral and other dietary supplements - None of the above | Medication | UKBB00000474 | 3.74e-04 |
| 10936 | Triglyceride levels in large HDL | GCST90092854 | 3.70e-04 |
| 10937 | XIAP levels | GCST90471083 | 3.70e-04 |
| 10938 | Fasting blood glucose | GCST000568 | 3.70e-04 |
| 10939 | ATOX1/SPARC ratio | GCST90313375 | 3.69e-04 |
| 10940 | Abdominal subcutaneous adipose tissue normalized | GCST90267348 | 3.69e-04 |
| 10941 | eosinophil (absolute count, minimum, inv-norm transformed) | GCST90475294 | 3.67e-04 |
| 10942 | SUSD4 levels | GCST90470788 | 3.66e-04 |
| 10943 | EREG/MPI ratio | GCST90314705 | 3.66e-04 |
| 10944 | GRAP2/TYMP ratio | GCST90314990 | 3.65e-04 |
| 10945 | DAG1/GP6 ratio | GCST90314375 | 3.64e-04 |
| 10946 | EPHB6/TNFRSF9 ratio | GCST90314682 | 3.64e-04 |
| 10947 | Carnitine levels | GCST90239991 | 3.61e-04 |
| 10948 | Plasma argininate* levels in chronic kidney disease | GCST90264826 | 3.61e-04 |
| 10949 | Mean reticulocyte volume | GCST90002396 | 3.61e-04 |
| 10950 | MTSS2 levels | GCST90469961 | 3.60e-04 |
| 10951 | ITGB1/VASN ratio | GCST90315232 | 3.58e-04 |
| 10952 | CPXM1/VEGFC ratio | GCST90314223 | 3.57e-04 |
| 10953 | Other acute lower respiratory infections | FING00000921 | 3.57e-04 |
| 10954 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T444 | ECGU000444 | 3.57e-04 |
| 10955 | LYN/TACC3 ratio | GCST90315350 | 3.55e-04 |
| 10956 | ERBB2/PTPRF ratio | GCST90314688 | 3.54e-04 |
| 10957 | ALCAM/LRRC25 ratio | GCST90313239 | 3.54e-04 |
| 10958 | HTRA2 levels | GCST90469494 | 3.53e-04 |
| 10959 | GMPR2 levels | GCST90469367 | 3.53e-04 |
| 10960 | C21orf58 levels | GCST90618380 | 3.52e-04 |
| 10961 | FCRL1/TCL1A ratio | GCST90314795 | 3.51e-04 |
| 10962 | CST3 levels | GCST90468894 | 3.50e-04 |
| 10963 | Urine X-24798 levels in chronic kidney disease | GCST90266802 | 3.50e-04 |
| 10964 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 3.48e-04 |
| 10965 | PDGFA/USP8 ratio | GCST90315621 | 3.48e-04 |
| 10966 | RNASE6 levels | GCST90470479 | 3.47e-04 |
| 10967 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 3.47e-04 |
| 10968 | Seropositive rheumatoid arthritis, wide | FING00001298 | 3.46e-04 |
| 10969 | CASP8/DDX58 ratio | GCST90313651 | 3.46e-04 |
| 10970 | RNASE1 levels | GCST90470476 | 3.45e-04 |
| 10971 | GP1BB levels | GCST90469381 | 3.45e-04 |
| 10972 | TNFRSF9 levels | GCST90470916 | 3.45e-04 |
| 10973 | Seborrhoeic dermatitis | FING00001282 | 3.45e-04 |
| 10974 | Phosphoglycerides levels | GCST90499265 | 3.44e-04 |
| 10975 | Type 1 diabetes | GCST90013791 | 3.43e-04 |
| 10976 | IFI30 levels | GCST90469509 | 3.43e-04 |
| 10977 | LRIG3 levels | GCST90469795 | 3.43e-04 |
| 10978 | CRACR2A/IRAG2 ratio | GCST90314227 | 3.42e-04 |
| 10979 | AIDA levels | GCST90468265 | 3.40e-04 |
| 10980 | Eosinophill count | Blood count | UKBB00000206 | 3.39e-04 |
| 10981 | In your lifetime, have you smoked a total of at least 100 cigarettes? | GCST90476387 | 3.38e-04 |
| 10982 | Cutaneous abscess, furuncle and carbuncle | FING00000373 | 3.37e-04 |
| 10983 | CCL5/TACC3 ratio | GCST90313707 | 3.34e-04 |
| 10984 | LRRFIP1 levels | GCST90469805 | 3.33e-04 |
| 10985 | CD58/IL10RB ratio | GCST90313850 | 3.33e-04 |
| 10986 | STK24 levels | GCST90470766 | 3.33e-04 |
| 10987 | EGF/MANF ratio | GCST90314609 | 3.33e-04 |
| 10988 | TARBP2 levels | GCST90470805 | 3.32e-04 |
| 10989 | VCAM1 levels | GCST90243317 | 3.32e-04 |
| 10990 | DECR1 levels | GCST90468978 | 3.29e-04 |
| 10991 | DRG2/SEMA4D ratio | GCST90314554 | 3.29e-04 |
| 10992 | ARHGAP25 levels | GCST90242651 | 3.27e-04 |
| 10993 | Ever had period extreme irritability | Mania | UKBB00000217 | 3.26e-04 |
| 10994 | NUDT5/SERPINB1 ratio | GCST90315581 | 3.26e-04 |
| 10995 | LRCH4 levels | GCST90469791 | 3.25e-04 |
| 10996 | IL2RA/NCR1 ratio | GCST90315161 | 3.24e-04 |
| 10997 | Atopic dermatitis | FING00000125 | 3.24e-04 |
| 10998 | Bread intake | Diet | UKBB00000105 | 3.23e-04 |
| 10999 | IDP SWI T2star left putamen | GCST90003867 | 3.22e-04 |
| 11000 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60) | GCST90320879 | 3.21e-04 |